Article
CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.
Haematologica - 1 Mar 2009
Johnson Nathalie A, Leach Stephen, Woolcock Bruce, deLeeuw Ronald J, Bashashati Ali, Sehn Laurie H, Connors Joseph M, Chhanabhai Mukesh, Brooks-Wilson Angela, Gascoyne Randy D
Abstract excerpt
Rituximab binds an epitope on the CD20 antigen, encompassed in exon 5 of the MS4A1 gene. We sequenced this region and correlated the presence of mutations with CD20 protein expression and response to R-CHOP in patients with diffuse large B-cell lymphoma: 264 diagnostic biopsies and 15 biopsies taken at the time of relapse were successfully sequenced. CD20 mutations involving the rituximab epitope were detected in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
